Journal Article Research Support, Non-U.S. Gov't Ppublish 21 citations
PubMed: 31463682 DOI: 10.1007/s13311-019-00775-8
Calming Down Mast Cells with Ketotifen: A Potential Strategy for Multiple Sclerosis Therapy?
Neurotherapeutics 17(1):218-234
Authors: Karen Henriette Pinke, Sofia Fernanda Gonçalves Zorzella-Pezavento, Thais Fernanda de Campos Fraga-Silva, Luiza Ayumi Nishiyama Mimura, Larissa Ragozo Cardoso de Oliveira, Larissa Lumi Watanabe Ishikawa, Ana Angélica Henrique Fernandes, Vanessa Soares Lara, Alexandrina Sartori
Affiliations
- Department of Microbiology and Immunology, Institute of Biosciences, São Paulo State University (UNESP), Rua Dr. Plinio Pinto e Silva, S/N, Distrito de Rubião Júnior, Botucatu, São Paulo, 18618-691, Brazil.
- Department of Microbiology and Immunology, Institute of Biosciences, São Paulo State University (UNESP), Rua Dr. Plinio Pinto e Silva, S/N, Distrito de Rubião Júnior, Botucatu, São Paulo, 18618-691, Brazil.
- Department of Chemistry and Biochemistry, Institute of Biosciences, São Paulo State University (UNESP), Botucatu, São Paulo, Brazil.
- Department of Surgery, Stomatology, Pathology and Radiology, Bauru School of Dentistry, University of São Paulo (USP), Bauru, São Paulo, Brazil.
Abstract
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS) characterized by extensive inflammation, demyelination, axonal loss and gliosis. Evidence indicates that mast cells contribute to immunopathogenesis of both MS and experimental autoimmune encephalomyelitis (EAE), which is the most employed animal model to study this disease. Considering the inflammatory potential of mast cells, their presence at the CNS and their stabilization by certain drugs, we investigated the effect of ketotifen fumarate (Ket) on EAE development. EAE was induced in C57BL/6 mice by immunization with MOG and the animals were injected daily with Ket from the seventh to the 17th day after disease induction. This early intervention with Ket significantly reduced disease prevalence and severity. The protective effect was concomitant with less NLRP3 inflammasome activation, rebalanced oxidative stress and also reduced T cell infiltration at the CNS. Even though Ket administration did not alter mast cell percentage at the CNS, it decreased the local CPA3 and CMA1 mRNA expression that are enzymes typically produced by these cells. Evaluation of the CNS-barrier permeability indicated that Ket clearly restored the permeability levels of this barrier. Ket also triggered an evident lymphadenomegaly due to accumulation of T cells that produced higher levels of encephalitogenic cytokines in response to in vitro stimulation with MOG. Altogether these findings reinforce the concept that mast cells are particularly relevant in MS immunopathogenesis and that Ket, a known stabilizer of their activity, has the potential to be used in MS control.
MeSH
Multiple Sclerosis, Therapeutics, Ketotifen, T-Lymphocytes, Mast Cells, Inflammasomes
Cited by
- Connecting the Dots in Emerging Mast Cell Research: Do Factors Affecting Mast Cell Activation Provide a Missing Link between Adverse COVID-19 Outcomes and the Social Determinants of Health? Med Sci (Basel), 2022
- Early life adversity drives sex-specific anhedonia and meningeal immune gene expression through mast cell activation. Brain Behav Immun, 2022
- Role of inflammasomes in multiple sclerosis and their potential as therapeutic targets. J Neuroinflammation, 2021
- Should mast cells be considered therapeutic targets in multiple sclerosis? Neural Regen Res, 2020
- Is there a window of opportunity for the therapeutic use of vitamin D in multiple sclerosis? Neural Regen Res, 2022
- Preclinical Therapy with Vitamin D3 in Experimental Encephalomyelitis: Efficacy and Comparison with Paricalcitol. Int J Mol Sci, 2021
- Focus on the Role of the NLRP3 Inflammasome in Multiple Sclerosis: Pathogenesis, Diagnosis, and Therapeutics. Front Mol Neurosci, 2022